Single agent activity of rhizoxin in non-small-cell lung cancer: A phase II trial of the EORTC Early Clinical Trials Group

被引:19
作者
Kaplan, S
Hanauske, AR
Pavlidis, N
Bruntsch, U
teVelde, A
Wanders, J
Heinrich, B
Verweij, J
机构
[1] TECH UNIV MUNICH,KLINIKUM RECHTS ISAR,D-81675 MUNICH,GERMANY
[2] UNIV IOANNINA,MED ONCOL SECT,GR-45110 IOANNINA,GREECE
[3] 5TH MED DEPT,D-90340 NURNBERG,GERMANY
[4] EORTC,NEW DRUG DEV OFF,1081 JC AMSTERDAM,NETHERLANDS
[5] ROTTERDAM CANC INST,DANIEL DEN HOED KLIN,3006 AE ROTTERDAM,NETHERLANDS
关键词
rhizoxin; phase II; non-small-cell lung cancer;
D O I
10.1038/bjc.1996.70
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In a multicentre trial of the EORTC-Early Clinical Trials Group (ECTG) we treated 31 chemotherapy-naive patients with advanced non-small-cell lung cancer (NSCLC) with rhizoxin, a novel tubulin-binding agent. The drug was given as an i.v. bolus injection at 2 mg m(-2) once every 3 weeks in an outpatient setting. Prophylactic antiemetics were not routinely given. Of the 29 eligible patients, nine had been treated surgically and three had received radiotherapy. The main toxic effects observed were stomatitis (34% of cycles) and neutropenia (41% of cycles). Neutropenic fever was rare (3% of cycles). Twenty-seven patients were evaluable for response. There were four partial responses (15%), while 13 patients (48%) showed stabilisation of their disease. The median duration of response was 7 months (range 6.0-10.7 months) and median survival from the start of rhizoxin treatment was 6 months (range 2-14.7 months). Rhizoxin as single agent shows activity in patients with advanced NSCLC.
引用
收藏
页码:403 / 405
页数:3
相关论文
共 10 条
[1]   CHEMOTHERAPY OF NON-SMALL CELL LUNG-CANCER - A REAPPRAISAL AND A LOOK TO THE FUTURE [J].
BAKOWSKI, MT ;
CROUCH, JC .
CANCER TREATMENT REVIEWS, 1983, 10 (03) :159-172
[2]  
BISSETT D, 1992, CANCER RES, V52, P2894
[3]   COMBINATION CHEMOTHERAPY VERSUS SINGLE AGENTS FOLLOWED BY COMBINATION CHEMOTHERAPY IN STAGE-IV NON-SMALL-CELL LUNG-CANCER - A STUDY OF THE EASTERN-COOPERATIVE-ONCOLOGY-GROUP [J].
BONOMI, PD ;
FINKELSTEIN, DM ;
RUCKDESCHEL, JC ;
BLUM, RH ;
GREEN, MD ;
MASON, B ;
HAHN, R ;
TORMEY, DC ;
HARRIS, J ;
COMIS, R ;
GLICK, J .
JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (11) :1602-1613
[4]   DOCETAXEL (TAXOTERE(TM)) IS ACTIVE IN NON-SMALL-CELL LUNG-CANCER - A PHASE-II TRIAL OF THE EORTC EARLY CLINICAL-TRIALS GROUP (ECTG) [J].
CERNY, T ;
KAPLAN, S ;
PAVLIDIS, N ;
SCHOFFSKI, P ;
EPELBAUM, R ;
VANMEERBEEK, J ;
WANDERS, J ;
FRANKLIN, HR ;
KAYE, S .
BRITISH JOURNAL OF CANCER, 1994, 70 (02) :384-387
[5]  
COHEN MH, 1979, PROGR THERAPEUTIC RE, P343
[6]   PRECLINICAL ANTITUMOR-ACTIVITY AND ANIMAL TOXICOLOGY STUDIES OF RHIZOXIN, A NOVEL TUBULIN-INTERACTING AGENT [J].
HENDRIKS, HR ;
PLOWMAN, J ;
BERGER, DP ;
PAULL, KD ;
FIEBIG, HH ;
FODSTAD, O ;
DREEFVANDERMEULEN, HC ;
HENRAR, REC ;
PINEDO, HM ;
SCHWARTSMANN, G .
ANNALS OF ONCOLOGY, 1992, 3 (09) :755-763
[7]   NEW AGENTS IN NON-SMALL CELL LUNG-CANCER [J].
JOSS, RA ;
CAVALLI, F ;
GOLDHIRSCH, A ;
MERMILLOD, B ;
BRUNNER, KW .
CANCER TREATMENT REVIEWS, 1984, 11 (03) :205-236
[8]   CHEMOTHERAPY CAN PROLONG SURVIVAL IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG-CANCER - REPORT OF A CANADIAN MULTICENTER RANDOMIZED TRIAL [J].
RAPP, E ;
PATER, JL ;
WILLAN, A ;
CORMIER, Y ;
MURRAY, N ;
EVANS, WK ;
HODSON, DI ;
CLARK, DA ;
FELD, R ;
ARNOLD, AM ;
AYOUB, JI ;
WILSON, KS ;
LATREILLE, J ;
WIERZBICKI, RF ;
HILL, DP .
JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (04) :633-641
[9]   CANCER RECURRENCE AFTER RESECTION - T1 N0 NON-SMALL CELL LUNG-CANCER [J].
THOMAS, P ;
RUBINSTEIN, L .
ANNALS OF THORACIC SURGERY, 1990, 49 (02) :242-247
[10]  
TSURUO T, 1986, CANCER RES, V46, P381